These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 24977690

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
    Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, El-Nowiem S.
    J Clin Oncol; 2015 Jan 10; 33(2):172-9. PubMed ID: 25488963
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Negri FV, Dal Bello B, Porta C, Campanini N, Rossi S, Tinelli C, Poggi G, Missale G, Fanello S, Salvagni S, Ardizzoni A, Maria SE.
    Liver Int; 2015 Aug 10; 35(8):2001-8. PubMed ID: 25559745
    [Abstract] [Full Text] [Related]

  • 10. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Arizumi T, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M.
    Dig Dis; 2014 Aug 10; 32(6):733-9. PubMed ID: 25376291
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM, STORM investigators.
    Lancet Oncol; 2015 Oct 10; 16(13):1344-54. PubMed ID: 26361969
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
    Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti P, Roth AD, Horber D, Buehlmann M, Wagner AD, Montemurro M, Lakatos G, Feilchenfeldt J, Peck-Radosavljevic M, Rauch D, Tschanz B, Bodoky G, Swiss Group for Clinical Cancer Research (SAKK).
    Ann Oncol; 2016 May 10; 27(5):856-61. PubMed ID: 26884590
    [Abstract] [Full Text] [Related]

  • 13. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
    Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E.
    J Clin Oncol; 2013 Nov 10; 31(32):4067-75. PubMed ID: 24081937
    [Abstract] [Full Text] [Related]

  • 14. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A.
    Oncology; 2018 Nov 10; 94(6):329-339. PubMed ID: 29719302
    [Abstract] [Full Text] [Related]

  • 15. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS.
    J Clin Gastroenterol; 2014 Mar 10; 48(3):e22-9. PubMed ID: 24045282
    [Abstract] [Full Text] [Related]

  • 16. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G, SARAH Trial Group.
    Trials; 2014 Dec 03; 15():474. PubMed ID: 25472660
    [Abstract] [Full Text] [Related]

  • 17. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Sarpel U, Spivack JH, Berger Y, Heskel M, Aycart SN, Sweeney R, Edwards MP, Labow DM, Kim E.
    HPB (Oxford); 2016 May 03; 18(5):411-8. PubMed ID: 27154804
    [Abstract] [Full Text] [Related]

  • 18. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.
    J Clin Oncol; 2013 Oct 01; 31(28):3509-16. PubMed ID: 23980090
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
    Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T.
    Ann Oncol; 2016 Nov 01; 27(11):2090-2096. PubMed ID: 27573564
    [Abstract] [Full Text] [Related]

  • 20. Sorafenib in liver function impaired advanced hepatocellular carcinoma.
    Ji YX, Zhang ZF, Lan KT, Nie KK, Geng CX, Liu SC, Zhang L, Zhuang XJ, Zou X, Sun L, Zhang ZC.
    Chin Med Sci J; 2014 Mar 01; 29(1):7-14. PubMed ID: 24698672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.